05.28.24
Ingredient supplier PhytoGaia and Monash University have partnered to conduct a human clinical trial which will assess the potential benefits of an ingredient called STGaia on improving the conditions of dry, aging skin. STGaia, a blend of squalene and palm tocotrienols, was formulated to address skin health and is the first ingredient of its kind to combine squalene and tocotrienols into a single complex.
The study, “Alterations in Skin Hydration, Moisture, and Genomic in Subejcts with Dry Skin Conditions following Daily Oral Palm Tocotrienol and Squalene (STGaia) Supplementation,” will be a randomized placebo-controlled trial evaluating measures of skin hydration, moisture levels, and genomic alterations among participants. The study is designed to both measure skin improvements while also shedding light on the potential effects on gene expression and skin health at the molecular level.
“We are thrilled to embark on this research partnership with Monash University,” said Bryan See, vice president at PhytoGaia. “This study represents a significant stride in our commitment to advancing the field of palm phytonutrients and skin care, particularly in addressing the effects of dry and aging skin. By leveraging on the expertise of Monash University’s esteemed researchers, we aim to uncover valuable insights into the efficacy of STGaia and its potential to enhance the lives of individuals dealing with dry skin conditions and age-related concerns. Another important aspect of this study is the nutrigenomic analyses that will provide a comprehensive understanding of how STGaia supplementation influences gene expression and skin at the molecular level, which has not been done before.”
This human clinical study is expected to further stimulate interest and investment in clinical research in Malaysia on palm-based phytonutrients, which will be an important downstream commercial activity for the country’s palm oil industry, PhytoGaia reports.
“We see great market potential in this research partnership, particularly with the aging demographic and the rising interest in natural beauty solutions in Malaysia and the world,” said See. “Teaming up with Monash University underscores our commitment, not only to furthering the science of palm phytonutrients but at the same time, adapting to consumer demands and driving forward-thinking approaches in skin care and anti-aging.”
“We are excited to collaborate with science-based companies such as PhytoGaia on this groundbreaking clinical trial,” said Dr. Shajahan Yasin, professor and Dean of Jeffrey Cheah School of Medicine and Health Sciences at Monash University Malaysia.
“Our institution is committed to conducting rigorous research that contributes to the advancements of our local resources and in healthcare to improve the well-being of individuals not only in Malaysia but worldwide,” said Dr. Kasthuri Bai Magalingam, principal investigator at Monash University. “By joining forces with PhytoGaia, we have the opportunity to explore innovative solutions for addressing skin conditions and enhancing overall skin health.”
The study, “Alterations in Skin Hydration, Moisture, and Genomic in Subejcts with Dry Skin Conditions following Daily Oral Palm Tocotrienol and Squalene (STGaia) Supplementation,” will be a randomized placebo-controlled trial evaluating measures of skin hydration, moisture levels, and genomic alterations among participants. The study is designed to both measure skin improvements while also shedding light on the potential effects on gene expression and skin health at the molecular level.
“We are thrilled to embark on this research partnership with Monash University,” said Bryan See, vice president at PhytoGaia. “This study represents a significant stride in our commitment to advancing the field of palm phytonutrients and skin care, particularly in addressing the effects of dry and aging skin. By leveraging on the expertise of Monash University’s esteemed researchers, we aim to uncover valuable insights into the efficacy of STGaia and its potential to enhance the lives of individuals dealing with dry skin conditions and age-related concerns. Another important aspect of this study is the nutrigenomic analyses that will provide a comprehensive understanding of how STGaia supplementation influences gene expression and skin at the molecular level, which has not been done before.”
This human clinical study is expected to further stimulate interest and investment in clinical research in Malaysia on palm-based phytonutrients, which will be an important downstream commercial activity for the country’s palm oil industry, PhytoGaia reports.
“We see great market potential in this research partnership, particularly with the aging demographic and the rising interest in natural beauty solutions in Malaysia and the world,” said See. “Teaming up with Monash University underscores our commitment, not only to furthering the science of palm phytonutrients but at the same time, adapting to consumer demands and driving forward-thinking approaches in skin care and anti-aging.”
“We are excited to collaborate with science-based companies such as PhytoGaia on this groundbreaking clinical trial,” said Dr. Shajahan Yasin, professor and Dean of Jeffrey Cheah School of Medicine and Health Sciences at Monash University Malaysia.
“Our institution is committed to conducting rigorous research that contributes to the advancements of our local resources and in healthcare to improve the well-being of individuals not only in Malaysia but worldwide,” said Dr. Kasthuri Bai Magalingam, principal investigator at Monash University. “By joining forces with PhytoGaia, we have the opportunity to explore innovative solutions for addressing skin conditions and enhancing overall skin health.”
